Zenas BioPharma, Inc. (ZBIO): Total Assets
$383.64M
As of 2025-12-31
$701.69M
As of 2026-06-30
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $383.64M | +3.7% | 2026-03-16, Balance as of period end |
| 2024-12-31 | $369.97M | +442.6% | 2026-03-16, Balance as of period end |
| 2023-12-31 | $68.18M | n/a | 2025-03-11, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | $383.64M | +3.7% |
| Janux Therapeutics, Inc. (JANX) | 2025-12-31 | $1.00B | -5.6% |
| Precigen, Inc. (PGEN) | 2025-12-31 | $155.50M | +7.0% |
| Prothena Corp Public Ltd Co (PRTA) | 2025-12-31 | $326.80M | -40.3% |
| Crescent Biopharma, Inc. (CBIO) | 2025-12-31 | $240.29M | +574.7% |
| International Stem Cell Corp (ISCO) | 2025-12-31 | $4.82M | -6.8% |
| BioAge Labs, Inc. (BIOA) | 2025-12-31 | $294.89M | -17.7% |
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | $38.32M | -28.3% |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | $5.71B | +5.0% |
Compare ZBIO, JANX, PGEN, PRTA side by side · Screen every company in Pharmaceutical Preparations ↗